Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

A Randomised, Four-period Cross-over Trial in Healthy Subjects, Investigating the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Soluble Insulin Aspart

This trial is conducted in Europe. The aim of this trial is to demonstrate a difference between the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in healthy subjects.

Inclusion Criteria:

• Body mass index between 18 and 28 kg/m^2 inclusive
• HbA1c within the normal laboratory range
• Non smoker for at least three months
• Females of childbearing potential using acceptable methods of contraception, including tubal ligation, an intrauterine device (IUD) , the oral contraceptive pill or barrier methods

Exclusion Criteria:

• Subjects who have received any investigational drug in the 3 months prior to the start of dosing
• Any disease requiring regular use of non topical prescription medicines
• Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug
• Any intercurrent illness or endocrine disorders that may affect blood glucose
• Subject with a history of drug or alcohol dependence
• Subject with a first degree relative with diabetes mellitus
• Subject with a history of clinically relevant allergic reactions to medical products
• Subjects who have donated any blood or plasma in the past 3 month preceding screening